Fresh savings just popped up! 25% off 3 or more products. | Start Saving >>
IGF-I Receptor β Blocking Peptide

IGF-I Receptor β Blocking Peptide #1525


IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma using IGF-I Receptor β Antibody #3027 in the presence of control peptide (left) or IGF-I Receptor β Blocking Peptide (right).

Learn more about how we get our images

This peptide is used to block IGF-I Receptor β Antibody #3027 reactivity in immunohistochemistry protocols.

The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry. The peptide blocks IGF-I Receptor β Antibody #3027 signal in immunohistochemistry.

Use as a blocking reagent to evaluate the specificity of antibody reactivity in immunohistochemistry protocol. For immunohistochemistry, add twice the volume of peptide as volume of antibody used in 100 µl total volume. Incubate for a minimum of 30 minutes prior to adding the entire volume to the slide. Recommended antibody dilutions can be found on the relevant product data sheet.


Supplied in 20 mM potassium phosphate (pH 7.0), 50 mM NaCl, 0.1 mM EDTA, 1 mg/ml BSA, 5% glycerol and 1% DMSO. Store at –20°C.

Insulin-like growth factor 1 (IGF-1) is a small (7.65 kDa) growth factor that interacts with both the IGF-1 receptor and the insulin receptor to control cell growth and apoptosis. Release of this endocrine hormone from the liver is stimulated by growth hormone produced in the anterior pituitary (1). Circulating IGF-1 is typically bound to one of six known IGF binding proteins (IGF-BP) (2). At target cells, the IGF-1 ligand binds IGF receptors (or insulin receptors) leading to receptor autophosphorylation and activation (3). Activated receptors mediate downstream signaling pathways (including Akt and MAPK) that regulate cell proliferation, apoptosis, development and longevity. Altered expression or mutation of IGF-1 is associated with several human disorders, including type I diabetes and various forms of cancer (4). Recombinant human IGF-1 has been used in clinical trials as a potential therapeutic agent in the treatment of human diseases (5).

  1. Le Roith, D. (1997) N Engl J Med 336, 633-40.
  2. Jones, J.I. and Clemmons, D.R. (1995) Endocr Rev 16, 3-34.
  3. Hernández-Sánchez, C. et al. (1995) J Biol Chem 270, 29176-81.
  4. Sandhu, M.S. (2005) Endocr Dev 9, 44-54.
  5. Trojan, J. et al. (2007) Neuroscience 145, 795-811.
Entrez-Gene Id
Swiss-Prot Acc.
For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Upstream / Downstream


Explore pathways related to this product.

Important Ordering Details

Custom Ordering Details: This product is assembled upon order. Please allow up to three weeks for your product to be processed.

To Purchase # 1525S

View sizes
Product # Size Price
100 µg $ 84.0

Related Products